Literature DB >> 9710893

Methotrexate and emerging therapies.

J M Kremer1.   

Abstract

It is likely that all new therapeutic interventions will be used with methotrexate in combination therapy. These combinations may yield real therapeutic advances. The potential for end organ toxicity, opportunistic infection, and malignancy will need to be carefully monitored with long-term, meticulously conducted observational studies. Expense, ease of use, and perceived benefit-to-risk ratio will determine which new agents become most commonly prescribed with methotrexate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710893     DOI: 10.1016/s0889-857x(05)70032-6

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  6 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Triple DMARD combination for rheumatoid arthritis resistant to methotrexate and steroid combination: a single-center experience.

Authors:  Metin Isik; Burcin Halacli; Ozgür Atmaca; Sezgin Etgül; Ismail Doğan; Levent Kılınç; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2012-11-15       Impact factor: 2.631

3.  Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis.

Authors:  J Wolf; T Stranzl; M Filipits; G Pohl; R Pirker; B Leeb; J S Smolen
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

4.  Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.

Authors:  P L C M van Riel; A J Taggart; J Sany; M Gaubitz; H W Nab; R Pedersen; B Freundlich; D MacPeek
Journal:  Ann Rheum Dis       Date:  2006-02-07       Impact factor: 19.103

5.  Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene.

Authors:  Y Berkun; D Levartovsky; A Rubinow; H Orbach; S Aamar; T Grenader; I Abou Atta; D Mevorach; G Friedman; A Ben-Yehuda
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

6.  Can Appropriate Systemic Treatment Help Protect the Cornea in Patients With Rheumatoid Arthritis? A Multidisciplinary Approach to Autoimmune Ocular Involvement.

Authors:  Manuel J Amador-Patarroyo; Emilio Jalil-Florencia; Oscar Otero-Marquez; Nicolás Molano-Gonzalez; Ruben D Mantilla; Adriana Rojas-Villarraga; Juan-Manuel Anaya; Carmen Barraquer-Coll
Journal:  Cornea       Date:  2018-02       Impact factor: 2.651

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.